The initial enthusiasm regarding the potential therapeutic benefits of PPARα agonists as activators of cardiac FAO and inhibitors of glucose utilization in the prevention and cure of myocardial infarction has not only been dampened by negative or not clearly beneficial outcomes in large clinical trials but also extremely contrasting results of experimental studies. This evidence concerns the gene PPARA and myocardial infarction.